Fedratinib in 2025 and beyond: indications and future applications
Abstract: Dysregulated JAK/STAT signaling underlies the pathogenesis of myelofibrosis, a myeloproliferative neoplasm characterized by cytopenias, splenomegaly, and constitutional symptoms. JAK inhibitors, such as fedratinib, are the primary therapeutic option for patients with high-risk or symptomat...
| Published in: | Blood Advances |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952925001041 |